| Date | Title | Description |
| 01.02.2021 | Startups see new promise in old insight about viruses to stop cancer | Photo: Main_sail, Getty Images
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent,... |
| 05.01.2021 | IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors | - |
| 05.01.2021 | IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors | Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Partners and Logos Capital
IconOVir formed by team behind Kite Pharma, Allogene Therapeutics an... |
| 05.01.2021 | IconOVir uncloaks with $77M, ex-Forty Seven CEO and cancer-killing viruses out of Salk Institute | When Gilead Sciences snapped up Forty Seven last year, CEO Mark McCamish could have called it a day. He joined a few boards and thought about retiring, but he's jumped back into the game because he felt a calling to contribute to the treatm... |
| 05.01.2021 | IconOVir Bio has announced a $77M Series A round to propel the company's pipeline of oncolytic virus programs into the clinic within the next 18 months to 2 years | - |
| 05.01.2021 | IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors | IconOVir Bio, Inc., a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced it has raised $77 million in a Series A financing. The... |
| 05.01.2021 | IconOVir Bio Raises $77 Million in Series A Financing | SAN DIEGO--(BUSINESS WIRE)--IconOVir Bio, Inc., a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced it has raised $77 million ... |
| - | Startups see new promise in old insight about viruses to stop cancer | For decades, scientists have known that viruses can kill cancer cells. The challenge has been harnessing that power safely and effectively.
Buoyed by advances in immunotherapy and drug discovery, a new wave of researchers and companies is p... |
